API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is being evaluated for the treatment of patients with locally advanced or metastatic biliary tract cancer.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Ampligen (Rintatolimod) is an intraperitoneally administered small molecule drug candidate, which is currently being evaluated in combination with pembrolizumab and cisplatin for the treatment of recurrent ovarian cancer.
Lead Product(s): Rintatolimod,Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) monoclonal antibody. It is approved for the treatment of resectable non-small cell lung cancer.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) monoclonal antibody, which is being evaluated in combinaton with chemoradiotherapy for the treatment of high-risk locally advanced cervical cancer.
Lead Product(s): Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2024
Details:
BMS receives U.S. FDA approval for Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) monoclonal antibody. It is being evaluated for the treatment of resectable non-small cell lung cancer.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.
Lead Product(s): VDA-1275,Sorafenib,Cisplatin
Therapeutic Area: Oncology Product Name: VDA-1275
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with chemotherapy for the treatment of resectable stage IIA to IIIB non-small cell lung cancer.
Lead Product(s): Nivolumab,Carboplatin,Cisplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
Keytruda (pembrolizumab) is a USFDA approved, PD-1 inhibitor. Now it is approved in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 stage III-IVA cervical cancer.
Lead Product(s): Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2024
Details:
Fortress expects to use the net proceeds for its operations, including, research and development and clinical trial expenditures of its pipeline, including CK-301 (cosibelimaba) fully-human monoclonal antibody of IgG1 subtype.
Lead Product(s): Cosibelimab,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions. It is under phase 3 clinical development for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC).
Lead Product(s): Toripalimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Loqtorzi (toripalimab-tpzi) is a PD-1 receptor inhibitor, enabling the immune system to activate and kill the tumor. It is approved for the first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Fortress expects to use the net proceeds for its operations, including, research and development and clinical trial expenditures of its pipeline, including Cosibelimaba fully-human monoclonal antibody of IgG1 subtype,
Lead Product(s): Cosibelimab,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 29, 2023
Details:
Loqtorzi (toripalimab-tpzi) is a PD-1 receptor inhibitor, enabling the immune system to activate and kill the tumor. It is approved for the first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy.
Lead Product(s): Toripalimab-tpzi,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Opdivo (nivolumab) is a PD-L1 Inhibitor Antibody drug candidate in combination with cisplatin/gemcitabine which is currently being evaluated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma via intravenous infusion.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2. It is being developed for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
USFDA grants priority review for Keytruda (pembrolizumab in combination with enfortumab vedotin and cisplatin) an antibody infusion therapy inhibiting PD-1, for the treatment of locally advanced or metastatic urothelial carcinoma.
Lead Product(s): Pembrolizumab,Enfortumab Vedotin,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
ADI-PEG 20 (pegargiminase) ia arginie degrader, which is being evaluated in phase 2/3 clinical trials in combination with cisplatin & pemetrexed for the treatment of malignant pleural mesothelioma.
Lead Product(s): Pegargiminase,Cisplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: ADI-PEG 20
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
Keytruda (pembrolizumab)- a monoclonal anti-PD-1 therapy in combination with fluoropyrimidine- & platinum-containing chemotherapy is approved for the treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GDJ adenocarcinoma.
Lead Product(s): Pembrolizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
The net proceeds will be used for the development of CK-301 (cosibelimab), an investigational fully-human monoclonal antibody that binds programmed death-ligand 1 and blocks its interaction with Programmed cell death protein 1.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 14, 2023
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is being evaluated in phase 3 clinical trials for the treatment of unresectable, Stage III non-small cell lung cancer.
Lead Product(s): Durvalumab,Cisplatin
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is approved for the treatment of patients with locally advanced or metastatic biliary tract cancer in China.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
The net proceeds will be used for the development of CK-301 (cosibelimab), an investigational fully-human monoclonal antibody that binds programmed death-ligand 1 and blocks its interaction with Programmed cell death protein 1.
Lead Product(s): Cosibelimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 10, 2023
Details:
Keytruda® (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
Keytruda (pembrolizumab) in combination with gemcitabine and cisplatin is approved for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
Opdivo (nivolumab) a programmed death-1 (PD-1) immune checkpoint inhibitor, in combination with cisplatin-based chemotherapy is being evaluated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
Lead Product(s): Nivolumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Hansizhuang (serplulimab) is a novel humanized monoclonal anti-PD-1 antibody, which is approved for the first-line treatment of extensive stage small cell lung cancer in combination with fluorouracil and etoposide.
Lead Product(s): Serplulimab,Cisplatin,Etoposide
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is being evaluated in combination with chemotherapy in phase 3 clinical trials for the treatment of EGFR-mutated advanced lung cancer and brain metastases.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
Opdivo (nivolumab) is a PD-1 inhibitor which is being evaluated along with chemotherapy in phase 3 clinical trials for the treatment of resectable non-small cell lung cancer.
Lead Product(s): Nivolumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
Keytruda (pembrolizumab), an anti-PD-1 therapy, is being developed in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Lead Product(s): Pembrolizumab,Trastuzumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Enfortumab Vedotin-ejf,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2023
Details:
Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
The EC approved KEYTRUDA (pembrolizumab) anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric cancer.
Lead Product(s): Pembrolizumab,Trastuzumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
TAS6417 (zipalertinib) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was engineered to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR.
Lead Product(s): CLN-081,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody, being developed for advanced cutaneous squamous cell carcinoma.
Lead Product(s): Cosibelimab,Cisplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: CK-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2023
Details:
Keytruda® (pembrolizumab), a humanized monoclonal anti-PD-1 therapy, receives positive opinion by CHMP recommending approval in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of GEJ adenocarcinoma.
Lead Product(s): Pembrolizumab,Trastuzumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Keytruda® (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody which promotes immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function.
Lead Product(s): Toripalimab,Cisplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
RRx-001 (nibrozetone) is a multifaceted small molecule inflammasome NLRP3/KEAP1 inhibitor with tumor-targeted cytotoxicity and healthy tissue cytoprotective properties, which is investigated for the treatment of small cell lung cancer.
Lead Product(s): RRx-001,Cisplatin
Therapeutic Area: Oncology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
The company intends to use the net proceeds for the development of INT230-6, a formulation consisting of its proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine.
Lead Product(s): 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Benchmark Company
Deal Size: $19.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 30, 2023
Details:
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. It is being investigated in combination with chemotherapy for resectable non-small cell lung cancer.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Keytruda (pembrolizumab) is a humanized mAb, anti-PD-1 therapy that blocks the interaction between PD-1 and its ligands, with chemotherapy, thereby activating T lymphocytes which may affect tumor cells in patients with Advanced Resectable Gastric cancer.
Lead Product(s): Pembrolizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Keytruda® (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Trastuzumab,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2023
Details:
Pemrydi RTU (pemetrexed) is indicated, in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberration..
Lead Product(s): Pemetrexed,Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Pemrydi RTU
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
Keytruda (pembrolizumab) is a humanized mAb, anti-PD-1 therapy that blocks the interaction between PD-1 and its ligands, with chemotherapy, thereby activating T lymphocytes which may affect tumor cells in patients with advanced or unresectable biliary tract cancer.
Lead Product(s): Pembrolizumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
Keytruda® (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2023
Details:
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. It is being investigated in combination with chemotherapy for resectable non-small cell lung cancer.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023